JP2014534981A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534981A5
JP2014534981A5 JP2014541285A JP2014541285A JP2014534981A5 JP 2014534981 A5 JP2014534981 A5 JP 2014534981A5 JP 2014541285 A JP2014541285 A JP 2014541285A JP 2014541285 A JP2014541285 A JP 2014541285A JP 2014534981 A5 JP2014534981 A5 JP 2014534981A5
Authority
JP
Japan
Prior art keywords
alkyl
halo
compound according
cycloalkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014541285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534981A (ja
JP6101279B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/064274 external-priority patent/WO2013074388A1/en
Publication of JP2014534981A publication Critical patent/JP2014534981A/ja
Publication of JP2014534981A5 publication Critical patent/JP2014534981A5/ja
Application granted granted Critical
Publication of JP6101279B2 publication Critical patent/JP6101279B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014541285A 2011-11-15 2012-11-09 Gpr119アゴニストとして有用な置換シクロプロピル化合物 Expired - Fee Related JP6101279B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161559897P 2011-11-15 2011-11-15
US61/559,897 2011-11-15
PCT/US2012/064274 WO2013074388A1 (en) 2011-11-15 2012-11-09 Substituted cyclopropyl compounds useful as gpr119 agonists

Publications (3)

Publication Number Publication Date
JP2014534981A JP2014534981A (ja) 2014-12-25
JP2014534981A5 true JP2014534981A5 (enExample) 2015-12-17
JP6101279B2 JP6101279B2 (ja) 2017-03-22

Family

ID=48430054

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014541285A Expired - Fee Related JP6101279B2 (ja) 2011-11-15 2012-11-09 Gpr119アゴニストとして有用な置換シクロプロピル化合物

Country Status (6)

Country Link
US (1) US9018224B2 (enExample)
EP (1) EP2780337B1 (enExample)
JP (1) JP6101279B2 (enExample)
AU (1) AU2012339870B2 (enExample)
CA (1) CA2855009C (enExample)
WO (1) WO2013074388A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957062B2 (en) 2011-04-08 2015-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012173917A1 (en) 2011-06-16 2012-12-20 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
EP2760855B1 (en) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
US9018200B2 (en) 2011-10-24 2015-04-28 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as GPR119 agonists
WO2017222713A1 (en) * 2016-06-24 2017-12-28 Indiana University Research & Technology Corporation A gpr119-based signaling system in the murine eye regulates intraocular pressure in a sex-dependent manner
SG11201811712QA (en) * 2016-07-01 2019-01-30 Pfizer 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
US10660334B2 (en) 2016-08-15 2020-05-26 Bayer Cropscience Aktiengesellschaft Fused bicyclic heterocycle derivatives as pesticides
BR112019020877A2 (pt) * 2017-04-05 2020-05-12 Bayer Cropscience Aktiengesellschaft Derivados de 2-amino-5-oxialquil-pirimidina e seu uso para controlar o crescimento de plantas indesejadas
EP3747888A4 (en) * 2018-02-01 2021-12-15 Japan Tobacco Inc. NITROGEN-ENRICHED HETEROCYCLIC AMIDE COMPOUND AND USES THEREOF FOR MEDICAL PURPOSES
KR102224677B1 (ko) * 2018-08-23 2021-03-08 가천대학교 산학협력단 티아졸로 피페라진 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물
JP2022552655A (ja) * 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
AU2021275038A1 (en) 2020-05-19 2022-12-22 Kallyope, Inc. AMPK activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
EP0970095B1 (en) 1997-03-07 2003-10-29 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2003514508A (ja) 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤/逆作用剤
DE69910045T2 (de) 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
PL352367A1 (en) 1999-05-17 2003-08-25 Novo Nordisk As Glucagon antagonists/inverse agonists
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
US6852738B2 (en) 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
CA2495943C (en) 2002-08-29 2009-07-21 Merck & Co., Inc. Indoles having anti-diabetic activity
CA2495915A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
AU2004207444B2 (en) 2003-01-17 2008-07-31 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
KR20070091038A (ko) 2004-12-24 2007-09-06 프로시디온 리미티드 G-단백질 결합 수용체(gpr116) 효능제 및 비만 및당뇨병을 치료하기 위한 이의 용도
US8193359B2 (en) 2004-12-24 2012-06-05 Prosidion Limited G-protein coupled receptor agonists
NZ564758A (en) 2005-06-30 2011-03-31 Prosidion Ltd G-protein coupled receptor agonists
BRPI0613505A2 (pt) * 2005-06-30 2011-01-11 Prosidion Ltd agonistas de gpcr
CL2008000017A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
AU2008267724A1 (en) 2007-06-28 2008-12-31 Merck Frosst Canada Ltd Substituted fused pyrimidines as antagonists of GPR105 activity
AU2008276568A1 (en) 2007-07-19 2009-01-22 Merck & Co., Inc. Beta carboline derivatives as antidiabetic compounds
EP2200609A1 (en) 2007-09-10 2010-06-30 Prosidion Limited Compounds for the treatment of metabolic disorders
MX2010003117A (es) 2007-09-20 2010-04-01 Irm Llc Compuestos y composiciones como moduladores de la actividad de gpr119.
US20110301079A1 (en) 2007-09-21 2011-12-08 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Neuromedin u receptor agonists and uses thereof
US8343990B2 (en) 2008-04-14 2013-01-01 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EA201170151A1 (ru) 2008-07-10 2011-08-30 Просидион Лимитед Пиперидиниловые агонисты gpcr
US20110230507A1 (en) 2008-07-10 2011-09-22 Prosidion Limited Piperidine GPCR Agonists
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812649D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812642D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
JP5538528B2 (ja) 2009-06-18 2014-07-02 カディラ・ヘルスケア・リミテッド 新規なgpr119アゴニスト
AR077638A1 (es) 2009-07-15 2011-09-14 Lilly Co Eli Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
WO2011019538A1 (en) 2009-08-13 2011-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
US20120053180A1 (en) 2010-08-27 2012-03-01 Chemizon, A Division Of Optomagic Co., Ltd. Cyclohexane analogues as gpr119 agonists
US8957062B2 (en) 2011-04-08 2015-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012173917A1 (en) 2011-06-16 2012-12-20 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
EP2760855B1 (en) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
US9018200B2 (en) 2011-10-24 2015-04-28 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as GPR119 agonists
WO2013122821A1 (en) 2012-02-14 2013-08-22 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
WO2014052379A1 (en) 2012-09-26 2014-04-03 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds

Similar Documents

Publication Publication Date Title
JP2014534981A5 (enExample)
JP2014506907A5 (enExample)
JP2017509689A5 (enExample)
JP2014518266A5 (enExample)
JP2016530259A5 (enExample)
JP2013510120A5 (enExample)
JP2016506935A5 (enExample)
EA201491329A1 (ru) 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201490419A1 (ru) Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания
JP2017514910A5 (enExample)
AR094918A1 (es) Compuestos de tetrahidropirrolotiazina como inhibidores de bace
JP2014507455A5 (enExample)
JP2013513621A5 (enExample)
JP2015500843A5 (enExample)
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
JP2014114295A5 (enExample)
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
JP2016040288A5 (enExample)
JP2014510147A5 (enExample)
JP2012513416A5 (enExample)
EA201391337A1 (ru) Ингибиторы hsp90
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
ECSP13012812A (es) Formulaciones inmunosupresoras
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда